Lisdexamfetamine dimesylate: In attention-deficit hyperactivity disorder in adults

CNS Drugs

Volumn 23, Issue 5, 2009, Pages 419-425

  Weber, Juliane ^a   Siddiqui, M Asif A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; AMINE OXIDASE (FLAVIN CONTAINING); CYTOCHROME P450 ISOENZYME; DEXAMPHETAMINE; LISDEXAMFETAMINE; LONG ACTING DRUG;

ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FOOD DRUG INTERACTION; HEADACHE; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NERVOUSNESS; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PULSE RATE; RATING SCALE; REVIEW; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FEMALE; HUMANS; MALE; QUESTIONNAIRES; YOUNG ADULT;

EID: 66249146083     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923050-00005     Document Type: Review

References (21)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366 (9481): 237-48
2. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007 Jan; 21(1): 10-41
3. Kessler RC, Adker L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716-23
4. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006; 67 (4): 524-40
5. Faraone SV. Lisdexamfetamine dimesylate: the first longacting prodrug stimulant treatment for attention deficit/ hyperactivity disorder. Expert Opin Pharmacother 2008 Jun; 9 (9): 1565-74
6. Shire US Inc. Prescribing information (US): Vyvanse® (lisdexamfetamine dimesylate) capsules [online]. Available from URL: http://www.vyvanse.com/pdf/prescribinginformation.pdf [Accessed 2008 Sep 30]
7. Blick SK, Keating GM. Lisdexamfetamine. Pediatr Drugs 2007; 9 (2): 129-35; discussion 136-8
8. Wigal SB, Kollins SH, Squires LA, et al. Lisdexamfetamine dimesylate demonstrated efficacy throughout the day up to 13 hours in an analog classroom study in children with attention-deficit/hyperactivity disorder [poster no. 1.24]. The 55th American Academy of Child & Adolescent Psychiatry Annual Meeting; 2008 Oct 28-Nov 2; Chicago (IL)
9. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. Epub 2009 Mar 27
10. Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. Epub 2008 Jul 17
11. Krishnan S, Zhang Y. Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. J Clin Pharmacol 2008 Mar; 48 (3): 293-302
12. Jasinski D, Krishnan S. Pharmacokinetics of oral lisdexamfetamine dimesylate (LDZ; NRP104) vs d-amfetamine in healthy adults with a history of stimulant abuse [poster no. 235]. The 16th US Psychiatric and Mental Health Congress; 2006 Nov 15-19; New Orleans (LA)
13. Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Invest 2008; 28 (12): 745-55
14. Ermer J, Homolka R, Martin P, et al. Linear dose proportionality, low inter- and intrasubject variability, and safety of lisdexamfetamine dimesylate in an openlabel single-dose pharmacokinetic study in healthy adult volunteers [poster no. 201]. The American College of Clinical Pharmacy Annual Meeting; 2008 Oct 19-22; Louisville (KY)
15. Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Curr Med Res Opin 2008 Jan; 24 (1): 33-40
16. Shojaei A, Ermer JC, Krishnan S. Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects [abstract no. NR740 plus poster]. The 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-25; San Diego (CA)
17. Krishnan S, Moncrief S. An evaluation of the cytochrome P450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 2007; 35 (1): 180-4
18. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attentiondeficit/hyperactivity disorder. J Clin Psychiatry 2008; 69: 1364-73
19. Weisler R, Young J, Mattingly G, et al. Long-term safety and efficacy of lisdexamfetamine dimesylate in adults with attention-deficit hyperactivity disorder [poster no. 206]. The 16th US Psychiatric and Mental Health Congress; 2008 Oct 30-Nov 2; San Diego (CA)
20. Niebler G, Wilens TE, Weisler R, et al. Evaluation of cardiovascular effects of lisdexamfetamine dimesylate treatment in adults with attention-deficit/hyperactivity disorder [abstract no. NR6-013 plus poster]. The 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC
21. Goodman DW, Mattingly G, Mattingly G. Effect of lisdexamfetamine dimesylate on sleep quality in adults with attention-deficit/hyperactivity disorder [abstract no. NR6-007]. The 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington, DC